A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982 to Prevent Lyme Disease in Healthy Participants (18 to 70 Years of Age)

NCT07561294 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

350

Enrollment

INDUSTRY

Sponsor class

Conditions

Lyme Disease

Interventions

BIOLOGICAL: mRNA-1982
BIOLOGICAL: Placebo

Sponsor

ModernaTX, Inc.